6,8-二溴-2-甲基咪唑并[1,2-A]吡嗪 | 1208082-91-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 中文名称: 6,8-二溴-2-甲基咪唑并[1,2-A]吡嗪
• 英文名称: 6,8-dibromo-2-methylimidazo[1,2-a]pyrazine
• CAS: 1208082-91-0
• 化学式: C₇H₅Br₂N₃
• 分子量: 290.945
• InChiKey: VBOLRIOORWFVNK-UHFFFAOYSA-N

物化性质

• 密度：
  2.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6,8-Dibromo-2-methylimidazo[1,2-a]pyrazine
CAS number: 1208082-91-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5Br2N3
Molecular weight: 290.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6,8-二溴-2-甲基咪唑并[1,2-A]吡嗪 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 氯仿 、 水 为溶剂， 反应 29.5h， 生成 6-(1H-indazol-4-yl)-2-methyl-8-morpholino-3-(piperidin-4-yl)imidazo[1,2-a]-pyrazine
  参考文献：
  名称：

  Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing

  摘要：

  该发明的第一个方面涉及一种磷脂酰肌醇3-激酶抑制剂，用于治疗或预防与棕色脂肪细胞中过氧化物酶体增殖物激活受体γ共激活因子1-α（Pgd1α）和/或解偶联蛋白1（热原蛋白/Ucp1）表达相关的疾病或病况。该疾病或病况可能与正能量失衡相关，例如肥胖、肥胖相关疾病或病况、脂肪肝和生物老化（性能老化）。该发明的另一个方面提供了使用磷脂酰肌醇3-激酶抑制剂促进个体体重减轻的方法。

  公开号：

  US09993554B2
• 作为产物：
  描述：

  一氯丙酮 、 2-氨基-3,5-二溴吡嗪 反应 16.0h， 以35%的产率得到6,8-二溴-2-甲基咪唑并[1,2-A]吡嗪
  参考文献：
  名称：

  Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing

  摘要：

  该发明的第一个方面涉及一种磷脂酰肌醇3-激酶抑制剂，用于治疗或预防与棕色脂肪细胞中过氧化物酶体增殖物激活受体γ共激活因子1-α（Pgd1α）和/或解偶联蛋白1（热原蛋白/Ucp1）表达相关的疾病或病况。该疾病或病况可能与正能量失衡相关，例如肥胖、肥胖相关疾病或病况、脂肪肝和生物老化（性能老化）。该发明的另一个方面提供了使用磷脂酰肌醇3-激酶抑制剂促进个体体重减轻的方法。

  公开号：

  US09993554B2

文献信息

• [EN] NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS EN TANT QUE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010089292A1

  公开（公告）日：2010-08-12

  The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

  本发明涉及式（I）的取代双环杂环化合物，其中Het1、Het2、A1、A2、A3和A4的含义如权利要求中所定义。根据本发明的化合物可用作γ-分泌酶调节剂。本发明还涉及制备这种新化合物的方法，包含所述化合物作为活性成分的药物组合物，以及将所述化合物用作药物的用途。
• [EN] HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE<br/>[FR] MODULATEURS HTT POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON
  申请人：CHDI FOUNDATION INC

  公开号：WO2021231571A1

  公开（公告）日：2021-11-18

  Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

  以下提供了一些作为HTT调节剂有用的化合物。这些化合物在亨廷顿病的治疗中很有用。
• IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS
  申请人：Pastor Fernández Joaquin

  公开号：US20120083492A1

  公开（公告）日：2012-04-05

  There is provided compounds of formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式(I)的化合物，其中R1、R2、R3、R4和R5在描述中有给定的含义，以及它们的药用可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要或期望抑制蛋白质或脂质激酶（例如PI3-K和/或mTOR）的疾病方面非常有用，特别是在治疗癌症或增生性疾病方面。
• [EN] FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS<br/>[FR] DÉRIVÉS DE PYRAZINE FUSIONNÉS UTILES EN TANT QUE STIMULATEURS DE LA GUANYLATE CYCLASE SOLUBLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2017197555A1

  公开（公告）日：2017-11-23

  Provided are certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ("cGMP"), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. Provided are also pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. Provided are also methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.

  提供了某些融合吡嗪化合物的公式(I)或其药学上可接受的盐，其中X、Y、R1、R3、R4a、R5a、R5b、R6和下标t在此描述。该化合物或其药学上可接受的盐可以调节体内环磷鸟苷酸单磷酸酯（“cGMP”）的产生，并且通常适用于治疗和预防与cGMP平衡紊乱相关的疾病或障碍。还提供了包括公式(I)化合物或其药学上可接受的盐的制药组合物。还提供了使用该化合物或其药学上可接受的盐在治疗和预防上述疾病和障碍以及为此制备制药品的方法。
• [EN] MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE D'URÉE MACROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022094012A1

  公开（公告）日：2022-05-05

  The present invention is directed to macrocyclic urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及宏环脲化合物，其是睡觉醒来素受体的激动剂。本发明还涉及所述化合物在潜在的涉及睡觉醒来素受体的神经和精神障碍和疾病的治疗或预防中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在涉及睡觉醒来素受体的这些疾病的预防或治疗中的用途。